Seroatlas · Human Serome Atlas

CRAT

Carnitine O-acetyltransferase

Also known as: CACP_HUMAN, CAT1

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P43155
Gene
CRAT
Ensembl
ENSG00000095321
Chromosome
9
Canonical length
626 aa
Protein class
Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins, Transporters
Subcellular location
Golgi apparatus,Cytosol

OverviewNCBI Gene

This gene encodes carnitine O-acetyltransferase, a member of the carnitine acyltransferase family and a key metabolic pathway enzyme which plays an important role in energy homeostasis and fat metabolism. This enzyme catalyzes the reversible transfer of acyl groups from an acyl-CoA thioester to carnitine and regulates the ratio of acyl-CoA/CoA. It is found in both the mitochondria and the peroxisome. Alternative splicing results in transcript variants encoding different isoforms that may localize to different subcellular compartments. [provided by RefSeq, Oct 2016]

Canonical amino-acid sequenceUniProt

626 residues, UniProt reviewed canonical sequence.

>P43155|CRAT
     1  MLAFAARTVV KPLGFLKPFS LMKASSRFKA HQDALPRLPV PPLQQSLDHY LKALQPIVSE
    61  EEWAHTKQLV DEFQASGGVG ERLQKGLERR ARKTENWLSE WWLKTAYLQY RQPVVIYSSP
   121  GVMLPKQDFV DLQGQLRFAA KLIEGVLDFK VMIDNETLPV EYLGGKPLCM NQYYQILSSC
   181  RVPGPKQDTV SNFSKTKKPP THITVVHNYQ FFELDVYHSD GTPLTADQIF VQLEKIWNSS
   241  LQTNKEPVGI LTSNHRNSWA KAYNTLIKDK VNRDSVRSIQ KSIFTVCLDA TMPRVSEDVY
   301  RSHVAGQMLH GGGSRLNSGN RWFDKTLQFI VAEDGSCGLV YEHAAAEGPP IVTLLDYVIE
   361  YTKKPELVRS PLVPLPMPKK LRFNITPEIK SDIEKAKQNL SIMIQDLDIT VMVFHHFGKD
   421  FPKSEKLSPD AFIQMALQLA YYRIYGQACA TYESASLRMF HLGRTDTIRS ASMDSLTFVK
   481  AMDDSSVTEH QKVELLRKAV QAHRGYTDRA IRGEAFDRHL LGLKLQAIED LVSMPDIFMD
   541  TSYAIAMHFH LSTSQVPAKT DCVMFFGPVV PDGYGVCYNP MEAHINFSLS AYNSCAETNA
   601  ARLAHYLEKA LLDMRALLQS HPRAKL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against CRAT can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Other membrane
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.23
Highest tissue expression
207 nTPM

Expression across tissuesHPA

Tissue

  • skeletal muscle: 207 nTPM
  • tongue: 188 nTPM
  • liver: 112 nTPM
  • testis: 96 nTPM
  • pancreas: 66 nTPM
  • heart muscle: 54 nTPM

Single-cell type

  • late spermatids: 977 nCPM
  • late primary spermatocytes: 299 nCPM
  • early spermatids: 191 nCPM
  • enterocytes: 142 nCPM
  • esophageal apical cells: 124 nCPM
  • esophageal suprabasal cells: 97 nCPM

Immune cell

  • myeloid DC: 8.6 nTPM
  • classical monocyte: 8.4 nTPM
  • MAIT T-cell: 6.7 nTPM
  • total PBMC: 6.1 nTPM
  • non-classical monocyte: 5.6 nTPM
  • intermediate monocyte: 5.5 nTPM

Brain region

  • pons: 46 nTPM
  • thalamus: 46 nTPM
  • medulla oblongata: 42 nTPM
  • cerebral cortex: 41 nTPM
  • midbrain: 41 nTPM
  • hypothalamus: 40 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about CRAT.

Disease | AllUniProt

Conditions CRAT is implicated in, by any mechanism.

  • Neurodegeneration with brain iron accumulation 8 (NBIA8) MIM:617917

Disease | GeneticClinVar

1 pathogenic / likely-pathogenic of 364 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

  • Neurodegeneration with brain iron accumulation 8

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.99
gnomAD pLI
0
gnomAD missense Z
0.85
DepMap mean gene effect
0.02
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads CRAT as an antibody target. Whether an autoantibody or antibody against CRAT could matter depends on whether native CRAT is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

CRAT is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label CRAT as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/CRAT. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...